Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Novo Nordisk A/S — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $29.97, while Novo Nordisk A/S trades at $45.93 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Invesco DB Commodity Index Tracking Fund pays none, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| DBC | NVO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $63.98 |
52-Week Low | $21.62 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
